ADC Biotechnology, a developer of anti-cancer drugs, has agreed a deal for new premises on the Deeside Industrial Park.

The business secured funding in September 2017 to support its expansion plans, with investors including Maven Capital Partners, Seneca and Finance Wales. The Welsh Government also provided a grant.

Insider Media reports FI Real Estate Management (FIREM) has now confirmed it has let the largest and last remaining unit at Deeside Industrial Park to the company. It was let for a term of twenty years at a headline rental of £4 per sq ft.

The 70,248 sq ft unit, formerly used for pharmaceutical manufacturing, will now be part of an expansion programme for ADC, enabling the company to manufacture antibody drug conjugates in all clinical phases and to provide small scale commercial production.

The first stage of development will involve the fit out of the existing unit for first in man and advanced clinical trials. As part of the work, ADC Bio will relocate its existing research and development activities from its current location at St Asaph Business Park.

ADC chief executive, Charlie Johnson, said “We look forward to working with the FIREM team on this initial project which is set to bring another 50 highly skilled jobs to Deeside. We anticipate more will follow as our operation grows.”

Matthew Pickles, FIREM estate manager at Deeside, said “We look forward to working with the company, which is one of the pioneers in the manufacture of the next generation of life-saving oncology therapeutics, to create a state of the art manufacturing facility for the future. They now join our other major tenants – Ralawise Ltd, UPS Limited, Akzo Nobel Packaging Coatings Ltd and Americk Packaging.”